• Stacy Lawlor

Global Non-Hodgkin Lymphoma Therapeutics Market Size to grow by US$ 12.14 Bn in 2030

The Global Non-Hodgkin Lymphoma(NHL) Therapeutics Market is projected to grow from USD 8.26 billion in 2021 to USD 12.14 billion by 2030 at a CAGR of 8.4% during the forecast period.

Request Free Sample To Learn More About This Report

The present trends of greater prevalence of practically all forms of cancers, including numerous types of NHLs, are the key drivers of this market for non-Hodgkin lymphoma treatment. Some NHL is particularly aggressive in nature, necessitating a precise treatment strategy. The use of effective and advanced non-Hodgkin lymphoma treatment items frequently results in better and good clinical outcomes. Many of these cancers have no symptoms until they have progressed to an advanced stage, at which point aggressive and effective therapies are required for better clinical outcomes. During the projected period, such factors are expected to contribute to the growth of the non-Hodgkin lymphoma therapy market.

Request Free Sample To Learn More About This Report

North America is the largest market for non-Hodgkin lymphoma (NHL) therapeutics due to the high prevalence and awareness of all sorts of cancer, including various types of blood malignancies such as non-lymphoma, Hodgkin's were some of the aspects that contributed to. As a result of these trends, expensive medicines for the treatment of non-lymphomas, Hodgkin's such as immunotherapies, have become popular. During the forecast period, Europe and Asia Pacific are expected to account for a considerable portion of the global market. The advent of innovative medicines such as CAR T-cell therapies, as well as increased awareness of the signs and treatment of non-Hodgkin lymphomas, is projected to fuel market growth in Europe. In Asia Pacific, pricey therapies like KYMRIAH have been approved by regulators, and the region also has a large prospective patient population, both of which are expected to contribute to market growth in Asia Pacific throughout the projection period.

Latin America and the Middle East & Africa are two other regions of the worldwide market that are still in the early stages of development. However, due to the expanding use of sophisticated medicines, these regions are seeing higher healthcare awareness and expenditure, which is expected to lead to substantial demand for advanced therapeutics during the forecast period.

Request Free Sample To Learn More About This Report


In December 2020, Calquence, AstraZeneca's cancer treatment for treating mantle cell lymphoma patients, achieved positive responses during its Phase 2 clinical trial, the company stated.

In June 2020, kyowa Kirin stated that their medicine POTELIGO is now available in Germany for the treatment of adult patients with uncommon malignancies such as mycosis fungoides and Sezary syndrome.

Read More Details On This Report: